The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
ABT-165 plus FOLFIRI vs bevacizumab (bev) plus FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine/oxaliplatin and bev.
 
Zev A. Wainberg
Consulting or Advisory Role - Aduro Biotech; Array BioPharma; Bristol-Myers Squibb; Five Prime Therapeutics; Genentech; Lilly; Merck; Merck KGaA; Novartis; Sirtex Medical
Research Funding - Five Prime Therapeutics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst)
Travel, Accommodations, Expenses - Genentech
 
Lan Wang
No Relationships to Disclose
 
Huibin Yue
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Monica Motwani
No Relationships to Disclose
 
Sreeneeranj Kasichayanula
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Martha Elizabeth Blaney
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Louie Naumovski
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
John H. Strickler
Consulting or Advisory Role - Amgen; Bayer; Celgene; Chugai/Roche; Genentech/Roche
Research Funding - Abbvie (Inst); Cascadian Therapeutics (Inst); Exelixis (Inst); Gilead Sciences (Inst); Leap Therapeutics; Macrogenics; MedImmune (Inst); OncoMed (Inst); Regeneron (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen